#Global Trends – Page 55 – HEALTHCARE INSIGHTS

Expedited Review Sought for New Higher-Dose Obesity Treatment

01/12/2025 Published by vivi

A pharmaceutical corporation has submitted a supplemental application for a higher dose semaglutide injectable (7.2 mg) to the U.S. Food... Read more

Global Strategic Restructuring: A Major Pharma Group’s Shift Toward Automation and Production Reallocation

01/12/2025 Published by vivi

The recent decisions by a leading Swiss pharmaceutical group highlight a broader trend within the industry: prioritizing automation, advanced manufacturing... Read more

Cost-Effective Solution for Retinal Diseases Enters European Market

01/12/2025 Published by vivi

On November 24, 2025, in Basel, Sandoz, a global leader in affordable medicines, announced the European launch of Afqlir® (aflibercept).... Read more

Sandoz Launches New Biosimilar Option in Europe

01/12/2025 Published by vivi

The Sandoz group has officially introduced Afqlir, its biosimilar referencing aflibercept, across various European markets. The drug received approval from... Read more

US Regulator Approves Spinal Gene Therapy

01/12/2025 Published by vivi

The U.S. Food and Drug Administration (FDA) has approved the intrathecal (spinal injection) formulation of the gene therapy onasemnogene abeparvovec,... Read more

Pharmaceutical Giant Commits Major U.S. Manufacturing Investment

01/12/2025 Published by vivi

The pharmaceutical corporation AstraZeneca announced a plan to invest $2 billion to expand its production capabilities within the state of... Read more

Tag: #Global Trends

Expedited Review Sought for New Higher-Dose Obesity Treatment

Global Strategic Restructuring: A Major Pharma Group’s Shift Toward Automation and Production Reallocation

Cost-Effective Solution for Retinal Diseases Enters European Market

Sandoz Launches New Biosimilar Option in Europe

US Regulator Approves Spinal Gene Therapy

Pharmaceutical Giant Commits Major U.S. Manufacturing Investment

Facebook

Map

Online Members